89 related articles for article (PubMed ID: 9470856)
21. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer].
Wang YJ; Wang N; Wang B; Qin WX; Xue CY
Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of p53 expression in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty KK
Anticancer Res; 1998; 18(1A):65-70. PubMed ID: 9568057
[TBL] [Abstract][Full Text] [Related]
23. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer.
Berclaz G; Altermatt HJ; Rohrbach V; Siragusa A; Dreher E; Smith PD
Int J Oncol; 2001 Dec; 19(6):1155-60. PubMed ID: 11713584
[TBL] [Abstract][Full Text] [Related]
24. E-cadherin expression in pleomorphic lobular carcinoma: an aid to differentiation from ductal carcinoma.
Wahed A; Connelly J; Reese T
Ann Diagn Pathol; 2002 Dec; 6(6):349-51. PubMed ID: 12478484
[TBL] [Abstract][Full Text] [Related]
25. Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma.
Lee WY; Jin YT; Tzeng CC
Anticancer Res; 1996; 16(5A):3007-12. PubMed ID: 8917421
[TBL] [Abstract][Full Text] [Related]
26. Expression of Bcl-2 protein in human primary breast carcinomas and its correlation with multifocality, histopathological types and prognosis.
Papadimitriou CS; Costopoulos JS; Christoforidou BP; Kotsianti AJ; Karkavelas GS; Hytiroglou PM; Koufogiannis DJ; Nenopoulou HE
Eur J Cancer; 1997 Jul; 33(8):1275-80. PubMed ID: 9301455
[TBL] [Abstract][Full Text] [Related]
27. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.
Krop IE; Sgroi D; Porter DA; Lunetta KL; LeVangie R; Seth P; Kaelin CM; Rhei E; Bosenberg M; Schnitt S; Marks JR; Pagon Z; Belina D; Razumovic J; Polyak K
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9796-801. PubMed ID: 11481438
[TBL] [Abstract][Full Text] [Related]
28. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
Boyault S; Drouet Y; Navarro C; Bachelot T; Lasset C; Treilleux I; Tabone E; Puisieux A; Wang Q
Breast Cancer Res Treat; 2012 Feb; 132(1):29-39. PubMed ID: 21512767
[TBL] [Abstract][Full Text] [Related]
29. Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression.
Kaya H; Bozkurt SU; Erbarut I; Djamgoz MB
Pathol Res Pract; 2008; 204(6):367-71. PubMed ID: 18342452
[TBL] [Abstract][Full Text] [Related]
30. Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast.
Bock N; Meden H; Regenbrecht M; Jünemann B; Wangerin J; Marx D
Anticancer Res; 2000; 20(1A):119-24. PubMed ID: 10769643
[TBL] [Abstract][Full Text] [Related]
31. [Expression of Twist, E-cadherin and N-cadherin in breast carcinoma and their clinical significance].
Ma YH; Wang K; Li L; Lu ZH; Chen J
Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):5-9. PubMed ID: 20388391
[TBL] [Abstract][Full Text] [Related]
32. Expression of c-kit in common benign and malignant breast lesions.
Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
[TBL] [Abstract][Full Text] [Related]
33. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
35. Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium.
Poulsom R; Hanby AM; Lalani EN; Hauser F; Hoffmann W; Stamp GW
J Pathol; 1997 Sep; 183(1):30-8. PubMed ID: 9370944
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time.
Bukholm IR; Husdal A; Nesland JM; Langerød A; Bukholm G
Breast Cancer Res Treat; 2003 Jul; 80(2):199-206. PubMed ID: 12908823
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1.
Neubauer H; Clare SE; Wozny W; Schwall GP; Poznanovic S; Stegmann W; Vogel U; Sotlar K; Wallwiener D; Kurek R; Fehm T; Cahill MA
Breast Cancer Res; 2008; 10(5):R85. PubMed ID: 18922159
[TBL] [Abstract][Full Text] [Related]
38. The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells.
Assmann V; Gillett CE; Poulsom R; Ryder K; Hart IR; Hanby AM
J Pathol; 2001 Sep; 195(2):191-6. PubMed ID: 11592098
[TBL] [Abstract][Full Text] [Related]
39. Expression of nuclear insulin receptor substrate 1 in breast cancer.
Sisci D; Morelli C; Garofalo C; Romeo F; Morabito L; Casaburi F; Middea E; Cascio S; Brunelli E; Andò S; Surmacz E
J Clin Pathol; 2007 Jun; 60(6):633-41. PubMed ID: 16882697
[TBL] [Abstract][Full Text] [Related]
40. [Analysis of the correlation between genetic and immunohistochemical markers (RB1, p16 and p53 gene regultors of a cell cycle) in sporadic mammary gland carcinoma].
Nemtsova MV; Zemliakova VV; Kuznetsova EV; Babenko OV; Zavalishina LE; Andreeva IuIu; Bateva MV; Frank GA; Zaletaev DV
Arkh Patol; 2007; 69(2):3-6. PubMed ID: 17642181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
